Compass Pathways Targets Late-2026 FDA Filing and 2027 US Launch for Its Psilocybin Product

Compass Pathways, the London-based company developing a synthetic psilocybin formulation known as COMP360, has set out its most concrete regulatory timeline to date. In its second-quarter and first-half 2026 results, announced on 5 August (US time), the company said it expects to complete its rolling New Drug Application (NDA) to the US Food and Drug Administration in the final quarter of 2026, and is preparing for a potential US commercial launch in the first half of 2027 — subject to FDA approval and rescheduling by the US Drug Enforcement Administration.

What the company announced

According to the company’s announcement, the FDA granted a rolling submission for COMP360 in April, following what Compass describes as positive results from two Phase 3 trials in treatment-resistant depression, both of which the company reports met their primary endpoints. Compass also holds one of the FDA’s National Priority Vouchers, which it says could shorten the agency’s review of a completed application to one to two months.

On its investor call, reported by Yahoo Finance and Seeking Alpha, the company said it has completed hiring its commercial leadership team and anticipates that treatment sessions would involve a minimum of around six hours of in-clinic monitoring, based on its trial protocols. Compass reported cash holdings of US$433.3 million at 30 June 2026, which it expects to fund operations into 2028.

Approval, if it comes, would still depend on steps beyond the FDA: psilocybin remains a Schedule I controlled substance in the United States, and a marketed product would require rescheduling decisions at both federal and state level.

The Australian picture

If the FDA approves COMP360 on this timeline, it would become the first approved psilocybin-based medicine in a major regulatory market — a development Australian readers may hear cited frequently. It would not change Australian law or access. In Australia, psilocybin can only be prescribed by TGA-authorised psychiatrists for treatment-resistant depression, using products that are not registered medicines on the Australian Register of Therapeutic Goods; registration of an approved product here would require a separate application to the TGA by a sponsor, which has not been announced. Compass’s announcement makes no mention of Australia.

Outside the authorised clinical pathway, psilocybin remains illegal to possess or supply in every Australian state and territory. These are company statements about a product under regulatory review, not evidence about any treatment’s effects.

If this article raises difficult feelings for you, support is available from Lifeline on 13 11 14.